Novartis: Entresto Gets Class I Recommendation In US,EU Heart Failure Guidelines

(RTTNews) - Novartis (NVS) announced that Entresto (sacubitril/valsartan) has been given a Class I recommendation in updated clinical practice guidelines simultaneously released by the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU. Entresto is a twice-a-day medicine that reduces the strain on the failing heart.

Novartis noted that US guidelines now recommend Entresto as standard of care for heart failure with reduced ejection fraction (HFrEF) as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto.

Novartis added that updated guidelines from the European Society of Cardiology recommend Entresto instead of an ACE or ARB in patients fitting the PARADIGM-HF profile.

Novartis specified that this guidance underscores the benefits of Entresto for patients to significantly reduce risk of death due to cardiovascular causes or heart failure hospitalization.